Price Performance and Market Position
As of the latest trading session, Shree Ganesh Biotech India’s share price is just 3.13% above its 52-week low of ₹0.62, signalling a near historic trough. The stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, underscoring a persistent downward momentum. Despite a flat day’s performance with no change recorded, the stock has underperformed the broader market indices over multiple time frames.
Comparatively, the Sensex posted a gain of 1.05% on the same day, while Shree Ganesh Biotech India remained static. Over the past week, the stock declined by 7.35%, contrasting with the Sensex’s modest 0.33% rise. The one-month and three-month periods show the stock falling by 16.00% and 17.11% respectively, while the Sensex advanced by 1.50% and 5.80% over the same intervals.
Longer-term performance figures reveal a more pronounced divergence. Over the past year, Shree Ganesh Biotech India’s shares have declined by 39.42%, whereas the Sensex has appreciated by 6.83%. Year-to-date figures mirror this trend, with the stock down 39.42% against the Sensex’s 9.38% gain. The three-year and five-year performances further illustrate the stock’s challenges, with losses of 65.38% and 86.96% respectively, while the Sensex recorded gains of 37.21% and 93.11% over the same periods. Notably, the stock’s 10-year performance remains flat at 0.00%, in stark contrast to the Sensex’s 229.26% rise.
Our current Stock of the Month is out! This Large Cap from Automobiles - Passenger Cars emerged as the single best opportunity from our elite universe. Get the details now!
- - Current monthly selection
- - Single best opportunity
- - Elite universe pick
Financial Health and Profitability Metrics
Shree Ganesh Biotech India’s financial data for the nine months ending September 2025 reveals a contraction in net sales to ₹5.16 crores, representing a decline of 44.64% compared to the previous period. Correspondingly, the company reported a net loss after tax (PAT) of ₹0.61 crores, also reflecting a 44.64% reduction in profitability.
The company’s ability to manage its debt obligations appears constrained, with an average EBIT to interest ratio of 0.91, indicating that earnings before interest and tax are insufficient to comfortably cover interest expenses. This ratio suggests a fragile debt servicing capacity.
Return on equity (ROE) averaged 2.62%, signalling limited profitability generated from shareholders’ funds. Additionally, the debtors turnover ratio for the half-year period stood at 0.00 times, pointing to potential inefficiencies in receivables management or collection processes.
Valuation and Risk Considerations
The stock’s valuation metrics indicate elevated risk relative to its historical averages. Over the past year, while the share price has declined by 39.42%, the company’s profits have contracted by approximately 86.6%, highlighting a disconnect between earnings performance and market valuation. This disparity may reflect investor caution given the company’s financial trajectory.
Majority shareholding remains with non-institutional investors, which may influence liquidity and trading dynamics in the stock.
Holding Shree Ganesh Biotech India from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Sector Context and Comparative Performance
Operating within the Pharmaceuticals & Biotechnology sector, Shree Ganesh Biotech India’s performance contrasts with broader sector trends. The stock’s recent outperformance relative to its sector by 1.36% on the day of the latest data is a minor deviation in an otherwise extended period of underperformance. The sector itself has shown resilience, with the Sensex and related indices posting gains over multiple time frames, underscoring the company’s relative challenges within its industry.
The company’s market capitalisation grade is noted as 4, reflecting its size and market presence within the sector. However, the persistent downward trend in share price and financial metrics suggests ongoing pressures that have yet to be alleviated.
Summary of Current Position
Shree Ganesh Biotech India’s stock has reached a historic low point, with financial indicators and market performance data underscoring a prolonged period of subdued results. The company’s sales and profitability have contracted significantly over recent periods, while its capacity to service debt remains limited. The stock’s valuation reflects elevated risk compared to historical norms, and its performance lags considerably behind broader market indices and sector peers.
These factors collectively illustrate the severity of the company’s current market standing, as it navigates a challenging environment within the Pharmaceuticals & Biotechnology sector.
Get 1 year of Weekly Picks FREE when you subscribe to MojoOne. Offer ends soon. Start Saving Now →
